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Abstract Equistatin is a protein composed of three thyroglo-
bulin type-1 domains. It inhibits papain-like cysteine proteinases
and the aspartic proteinase, cathepsin D. To determine the
structural basis for this inhibition we cloned and expressed the
separated domains (eq d-1, eq d-2, eq d-3) in Pichia pastoris.
Kinetic constants for the interaction of eq d-1 with papain and
that of eq d-2 with cathepsin D are of similar order (subnano-
molar) and are comparable to the constants obtained for full-
length equistatin. The target proteinase for the third domain
remains unknown. Thus, we demonstrate here that thyroglobulin
type-1 motifs per se are able to support speci¢c structural fea-
tures that enable them to inhibit proteases from di¡erent
classes. The overall conformation of three domains in equistatin
is such that the interaction of domains 1 or 2 with their respec-
tive target enzymes is not hindered sterically by either domain.
In addition, we show that the interaction of eq d-2 with cathep-
sin D results in conformational changes, which is not the case
for the eq d-1/papain interaction.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Equistatin is a 22 kDa protein from the sea anemone, Ac-
tinia equina. It is composed of three V65-amino acid thyro-
globulin type-1 domains (Thyr-1) [1,2]. Similar domains are
also present in single or multiple copies in many structurally
and functionally diverse proteins [3,4]. Among them, equista-
tin [1], saxiphilin [5], ECI [6] and p41 invariant chain fragment
[7] have been classi¢ed, on the basis of the ability to inhibit a
variety of papain-related cysteine proteinases, as thyroglobulin
type-1 domain proteinase inhibitors, also called thyropins [4].
Of these four inhibitors, equistatin is unusual in also inhibit-
ing an aspartic proteinase, cathepsin D [8].
Thyropins bind reversibly and tightly to cysteine protein-
ases. The general mechanism of the interaction of Thyr-1
domains with cysteine proteinases was demonstrated by the
crystal structure of p41 invariant chain fragment in complex
with cathepsin L. The wedge shape of the p41 fragment is
anchored into the active site cleft and the interaction is medi-
ated through the three loops of the p41 fragment [9]. In con-
trast to equistatin, which exhibits broad inhibitory speci¢city
towards cysteine proteinases [1,10], the p41 fragment can dis-
criminate between the two very similar cysteine proteinases,
cathepsins L and S [7].
Only a few naturally occurring protein inhibitors of aspartic
proteinases have been found. Two completely di¡erent mech-
anisms of inhibition have been described, one based on adopt-
ing an K-helical conformation of IA3 upon interaction with
enzyme [11] and the second based on pairing of L-sheets of PI-
3 and pepsin near the active site cleft of the enzyme [12].
There are no data on the mechanism of the inhibition of ca-
thepsin D by thyroglobulin type-1 domain.
The existence of the Thyr-1 domains in such a variety of
proteins raises questions about their activity and function, and
about their possible interactions with neighboring domains.
Equistatin serves as a good model for such a study. Our
aims were, ¢rstly, to locate the cathepsin D inhibition activity
more precisely; secondly, to compare the inhibitory properties
of the separate domains with those of equistatin; and thirdly,
to look for structural changes upon their interaction with their
target enzymes. The individual domains were therefore pre-
pared as recombinant proteins in Pichia pastoris, enabling de-
tailed kinetic and Circular dichroism (CD) measurements to
be made.
2. Materials and methods
2.1. Materials
Materials for cloning, expression and puri¢cation were obtained
from the following sources: restriction endonucleases, DNA ligase,
Taq polymerase, deoxynucleotide from Gibco BRL (The Nether-
lands), salts and media for P. pastoris from Difco (USA), P. pastoris
expression kit, pPIC9 plasmid and P. pastoris strain GS115 from
Invitrogen (USA), Sephadex G-50 and Phenyl^Sepharose from Amer-
sham Pharmacia Biotech (UK). Equistatin [13], papain [14] and bo-
vine cathepsin D [15] were puri¢ed as described. Pepstatin was from
Sigma (Germany), H-Pro-Thr-Glu-Phe-Phe(NO2)-Arg-Leu-OH from
Novabiochem (Germany) and Ac-EE(Edans) KPICFFRLGK(Dab-
cyl)E-NH2 from CSPS Pharmaceuticals (USA).
2.2. Cloning and expression of individual domains of equistatin
The individual domains of equistatin, eq d-1 (residues 1^67), eq d-2
(residues 68^135) and eq d-3 (residues 136^199) were created by poly-
merase chain reaction (PCR) employing a plasmid-encoding full-
length equistatin as the template [13] and using 5P-CCCGAAC-
AGAAAAGAGAGGCTGAAGCTAGTCTAACGAAATGCCAAC-
AG-3P- (eq d-1), 5P-CCTCGCGAACTCGAGAAAAGAGAGGC-
TGAAGCTGCTGCCTTAACACTTTGCCAGT-3P (eq d-2) or 5P-
CCCGAACTCGAGAAAAGAGAGGCTGAAGCTAGCGAATGC-
GAGGAGGCTCGT-3P, (eq d-3) as the forward primers and 5P-GG-
ATCCGCGGCCGCTTATTTTCTGCGACTGCAGTCTGG-3P (eq
d-1), 5P-GGATCCGCGGCCGCTTATAGGTGTCTTTCGCAGGT-
TGG-3P (eq d-2) or 5P-GGATCCGCGGCCGCTTAGCATGTGG-
GACGTTTGAATCTG-3 (eq d-3) as the reverse primers. All frag-
ments were subcloned into the pPIC9 expression vector by digestion
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with XhoI and NotI. The expression vectors pPIC9eqd-1, pPIC9eqd-2
and pPIC9eqd-3 were introduced into P. pastoris strain GS115 by
electroporation with Gene Pulser Electroporator (Bio-Rad, USA).
The transformants were selected on MD agar plates, the selected
colonies were inoculated in 10 ml of bu¡ered liquid BMG medium
and incubated at 30‡C with shaking to an A600 of 2.0 (V12 h). Cells
were recollected by centrifugation (2500Ug for 5 min at 23‡C) and
gently resuspended in 10 ml of bu¡ered BMM medium and cultured a
further 3 days to induce expression. The production of the cloned
inhibitors was monitored by electrophoretic analysis of the superna-
tant on sodium dodecyl sulfate (SDS) gels according to Laemmli [16].
Large-scale production in bioreactor was carried out as described in
[17].
2.3. Puri¢cation of the expressed domains
The culture supernatant was processed by two chromatographic
steps. Eq d-1 was puri¢ed by a⁄nity chromatography on CM-papain
Sepharose followed by gel chromatography on Sephadex G-50. Eq d-2
and eq d-3 were puri¢ed by hydrophobic interaction chromatography
on Phenyl^Sepharose and eluted with a gradient of 1.5^0 M ammo-
nium sulfate as described in [18]. The identities of individual recombi-
nant domains were con¢rmed by analysis of the N-terminal residues.
2.4. Inhibition kinetics of papain and cathepsin D
The kinetics of inhibition of papain with eq d-1 [1] and the equi-
librium dissociation constant for the interaction of cathepsin D with
eq d-2 and pepstatin were determined as described in [8]. Association
rate constants for the interactions of equistatin, eq d-2 and pepstatin
with cathepsin D were determined by continuous measurements under
pseudo-¢rst-order conditions at 25‡C. The decrease of enzymatic ac-
tivity was monitored with a DX 17MV stopped-£ow apparatus (Ap-
plied Photophysics, UK). One syringe was ¢lled with 0.1 M sodium
acetate bu¡er, pH 4.1, inhibitor (¢nal concentration in the range from
24 to 120 nM), and substrate Ac-EE(Edans)KPICFFRLGK(Dab-
cyl)E-NH2 (5 WM) while the second one was ¢lled with cathepsin D
(3 nM) in the same bu¡er. 100 Wl of solution from each syringe was
used per run, and an average of six to eight runs was performed for
each inhibitor concentration. The emission of released products was
observed using an excitation wavelength of 349 nm and a cut-o¡ ¢lter
with V50% transmission at 420 nm. The progress curves were ¢tted
by non-linear regression according to Morrison [19]: [P] = vst+
(vz3vs)(13e3kt)/k, where [P] is the product concentration, vz and vs
are the initial and the steady-state velocities, respectively, t is time,
and k is the observed rate constant. Association rate constants, ka,
were obtained from the slope of the linear plot of k vs. [I] (slope=
ka[I]/(1+[S]/Km)+kd). The ka values were corrected for substrate com-
petition with the use of a Km value of 4.5 WM [20]. The dissociation
rate constants, kd, were calculated from kd =Kika, where Ki was de-
termined by the equilibrium method.
2.5. CD
Measurements were performed on an Aviv 60DS spectrometer us-
ing a quartz cell with 0.2 mm path length. In the wavelength region
250^185 nm, data points were recorded at 1 nm intervals with a dwell
time of 10 s. The active concentrations of the enzymes (papain, ca-
thepsin D) and the inhibitors (equistatin, eq d-1, eq d-2) were deter-
mined by titration as described in [1,8]. They were in the range of 80^
100%. Extinction coe⁄cients for proteins were calculated using the
molar extinction coe⁄cients of aromatic amino acids [21]. The ratio
between the active concentrations was 1:1 in the case of eq d-1 and
papain, and 1.1:1 for eq d-2 and cathepsin D. Eq d-1, papain and
complex were scanned in 10 mM sodium phosphate, pH 6.0, and eq
d-2, cathepsin D and its complex in 100 mM sodium phosphate, pH
3.2. The CD spectra of equistatin and its individual domains were
measured in 100 mM sodium phosphate, pH 7.0. To avoid the auto-
degradation of enzymes the temperature of scanning was 4‡C. In
order to con¢rm the absence of turbidity the absorbance of protein
solutions was scanned from 350 to 240 nm (Perkin Elmer lambda 18
spectrophotometer) prior to CD measurements.
3. Results
3.1. Recombinant domains
The yield of expressed eq d-1 domain in the medium, de-
termined by titration with papain, was up to 1 g/l. The
amounts of eq d-2 and eq d-3 were in the same range, as
estimated from SDS^PAGE gels, where the band of eq d-1
served as the reference. The ¢nal yields of the puri¢ed do-
mains were V800, V300 and V300 mg/l for eq d-1, eq d-2
and eq d-3, respectively. The main loss of eq d-2 and eq d-3
was observed during Phenyl^Sepharose chromatography,
where the proteins tended to aggregate. No major loss oc-
curred during the ¢nal puri¢cation step on Sephadex-G50.
Puri¢ed domains were analyzed on SDS^PAGE gel and in
all cases a single band corresponding to an Mr of about
7000 was observed (data not shown). The purity of each do-
main was characterized by N-terminal sequencing. All three
domains started with EAEA, followed by their characteristic
sequences [13]. The EAEA sequence corresponds to a gluta-
mic acid^alanine repeat which is normally e⁄ciently removed
by the yeast STE13 protease [22].
3.2. Kinetic characterization
The puri¢ed recombinant domains were tested for their
ability to inhibit papain and cathepsin D (Table 1). Eq d-1
inhibited only papain and eq d-2 inhibited only cathepsin D
with Ki values closely similar to those determined for equista-
tin. Association and dissociation rate constants for the inhi-
bition of cathepsin D by eq d-2, native equistatin and pepsta-
tin were determined by stopped-£ow and slow-binding kinetic
techniques. A linear dependence of k on inhibitor concentra-
tion was observed for all three inhibitors investigated (Fig. 1),
consistent with simple, competitive inhibition [19]. The rate
constants (ka) for the binding of inhibitors to cathepsin D
were calculated from the slopes of these plots. Pepstatin ex-
hibited almost three-fold higher ka values than those obtained
for equistatin and eq d-2. The kd values could not be deter-
mined from these measurements, as the intercept on the ordi-
Table 1
Kinetic data for the interaction of papain and cathepsin D with equistatin, equistatin domains and pepstatin
Enzyme Inhibitor 1036Uka 104Ukd Ki
(M31 s31) (s31) (nM)
Papain equistatin 3.5 S 0.3a 6.3 S 0.3a 0.18S 0.01a;b
eq d-1 4.5 S 1.0 11.6S 0.3 0.26S 0.06b
Cathepsin D equistatin 2.8 S 0.1 14.0S 6.3 0.5 S 0.2a;c
eq d-2 3.1 S 0.2 15.5S 8.4 0.5 S 0.3c
pepstatin 8.0 S 0.1 0.8 S 0.02 0.01S 0.006c
Error estimates for Ki were calculated from the square root of the sum of the relative squared errors for ka and kd assuming that variance is
additive.
aResults previously published [17].
bDetermined by kinetic measurements.
cDetermined by equilibrium method.
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nate was indistinguishable from zero. However, the kd values
were calculated from Ki (determined by the equilibrium meth-
od) and ka (Table 1). The much lower Ki value for the inter-
action of cathepsin D with pepstatin (0.01 nM) than with eq
d-2 (0.5 nM) re£ects the slower dissociation rate for pepstatin
(Table 1).
3.3. Structure analysis by CD spectroscopy
The far-UV CD spectra of equistatin and its domains are
shown in Fig. 2. The spectrum of eq d-1 was shown to be
independent of ionic strength in the range 10^100 mM (data
not shown). The trough at 200 nm of eq d-1 and eq d-2 is
typical of proteins that show no regular secondary structure
[23], although a L-structure is also possible (see Section 4).
The positive peak around 220 nm in eq d-2 is reported to
re£ect an aromatic contribution [24], and this could also cause
a shift of the spectrum to lower wavelengths. It cannot be
ruled out, however, that the fold of this domain di¡ers sig-
ni¢cantly from those of the other two. In addition, the equi-
statin spectrum was superimposed on the summed spectra of
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Fig. 1. Dependence of the pseudo-¢rst-order rate constant k on in-
hibitor concentration for the interaction of cathepsin D with equi-
statin (b), eq d-2 (E) and pepstatin (R). Solid lines were obtained
by linear regression according to Morrison [27].
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Fig. 2. A: Far-UV CD spectra of eq d-1 (b), eq d-2 (*) and eq d-3
(a). B: Comparison of the CD spectrum of equistatin (E) and the
sum of the spectra for eq d-1, eq d-2 and eq d-3 (F).
260250240230220210200190180
8
6
4
2
0
-2
-4
-6
-8
-10
 
 (
m
d
e
g
)
A
260250240230220210200190180
2
1.5
1
0.5
0
-0.5
-1
-1.5
-2
-2.5
-3
-3.5
 
 (
m
d
e
g
)
B
θ
θ
Wavelength (nm)
Wavelength (nm)
Fig. 3. A: Far-UV CD spectra of eq d-2 (b), cathepsin D (a) and
the complex of the two (*). B: Comparison of the observed CD
spectrum of eq d-2 (b) with the spectrum obtained by subtraction
of the CD spectrum of cathepsin D from that of the complex (O).
The CD spectra were recorded at concentrations of 12.8 WM for ca-
thepsin D, 28.1 WM for eq d-2 and the mixed sample contained 7.7
WM of cathepsin D and 11.0 WM of eq d-2.
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the individual domains (Fig. 2B), showing that the domains in
equistatin do not in£uence each other’s conformation.
In order to explore the possibility suggested by the work on
the Saccharomyces inhibitor IA3, that the inhibitor^aspartic
protease interaction can result in conformational change [11],
the spectrum of eq d-2 was compared with the one obtained
by subtraction of the spectrum of cathepsin D from that of
the complex. There is a signi¢cant shift towards the spectra of
eq d-1 and eq d-3, characterized by a trough at 200 nm (Fig.
3). The possibility that the change is occurring in cathepsin D,
or in both, cannot, at this stage, be ruled out.
The analogous experiment was carried out with papain and
eq d-1 (Fig. 4). The only di¡erence between the spectra for the
free and complexed domain is in intensity, which could be due
to a slight tightening up of their conformations resulting from
the expected mutual stabilization.
4. Discussion
The expression system in P. pastoris developed here for the
individual equistatin domains gave quantities su⁄cient for
their functional and structural characterization. The remark-
able expression levels were obtained by using the bioreactor,
in which higher cell concentrations and strictly controlled cul-
tivation conditions can be achieved. The expression system
adopted was that previously used for the production of full-
length equistatin in P. pastoris, where the yield of expressed
protein was also up to 1 g/l [17,18]. In contrast, the attempted
production of individual equistatin domains in Escherichia
coli resulted in yields of less than 1 mg/l [25].
Previous studies on native equistatin gave a detailed de-
scription about the kinetics of the interaction of equistatin
and eq d-1 with cysteine proteinases, while the interaction
of equistatin with cathepsin D was characterized only by the
determination of its equilibrium dissociation constant [1,8].
No information about rate constants for aspartic protein-
ase^inhibitor interactions is available. The interaction of ca-
thepsin D with equistatin, eq d-2 and pepstatin was studied
under pseudo-¢rst-order conditions in the presence of a highly
sensitive £uorogenic substrate that enabled us to follow the
progressive inhibition. The pseudo-¢rst-order rate constant
increases linearly with inhibitor concentration, indicating a
simple bimolecular process. The interaction of all the inhib-
itors tested with cathepsin D resulted in the rapid formation
of tight complexes. The higher inhibitory potency of pepstatin
is a consequence of lower dissociation rate, which is in agree-
ment with the fact that pepstatin in the complex with cathep-
sin D is stabilized by the numerous hydrogen bonds between
backbone atoms of the inhibitor and both main and side
chain atoms of the enzyme [26].
The sequence similarity of known thyroglobulin type-1 do-
mains suggests that they share a common fold. Indeed, most
of the conserved residues are in positions that stabilize the
fold present in the p41 fragment [4,9]. Although interpretation
of the spectra of equistatin domains is ambiguous (see Section
3), those of eq d-1 and eq d-3 are closely similar, indicating
similar backbone conformations. The spectra are very similar
to those of a group of small L-structure proteins including the
WWW domain [27], certain SH3 domains [28,29], and CspA
[30], and also of clitocypin, a larger protein with a high L
content [31]. The content of K-helix in the p41 invariant chain
fragment, and presumably in the equistatin inhibitory do-
mains, is small (nine residues out of 64 total [9]) and would
only make a small contribution to the spectrum. Thus the
most reasonable interpretation of the far-UV spectra is that
the L structure in thyroglobulin type-1 domains is such as to
give the same type of CD spectrum as the WWW L-structure
domains. The spectrum of free eq d-2 di¡ers somewhat (Fig.
2) in showing a marked aromatic contribution and probably a
di¡erent backbone conformation. It is interesting that inter-
action of eq d-2 with cathepsin D induces a change which,
when analyzed in terms of the spectrum of the domains, re-
sults in a spectrum similar to those of the other two domains
(Fig. 3). This may re£ect the kind of induced conformation
observed with the IA3 inhibitor [11]. No such change was
observed with papain and eq d-1.
Eq d-3 did not inhibit either papain or cathepsin D. This is
consistent with the previous ¢nding that equistatin can only
bind two enzyme molecules, but it was not clear whether this
was due to the topology of the intact molecule which could
sterically hinder the approach of an enzyme [8]. Provided that
this domain is properly folded ^ the similarity of its spectrum
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Fig. 4. A: Far-UV CD spectra of eq d-1 (P), papain (E) and the
complex of the two (R). B: Comparison of the observed CD spec-
trum of eq d-1 (b) with the spectrum obtained by subtraction of
CD spectra of that for papain from that of the complex (O). Spec-
tra were recorded at concentrations of 12.0 WM for papain, 35.0
WM for eq d-1 and the mixed sample contained 12.0 WM of papain
and 13.0 WM of eq d-1.
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to that of the active eq d-1 supports the native fold ^ this
explanation is now excluded. It remains to be seen whether it
has another speci¢city or function.
The evidence now available supports a topological model of
the intact equistatin in which the domains do not a¡ect each
other’s conformation or activity. This is based on the demon-
strated additivity of the CD spectra of the individual domains.
It is also supported by the similarity of the association rate
constants and binding constants of the two domains for the
two enzymes to those of the whole equistatin. It will be inter-
esting to discover whether the domains are packed or £exibly
linked.
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